Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report

2020-06-30
Price :
Published : Jun-2020
No. of Pages : 34
Table of Contents
1. Market Cap Change for Bio/Pharma Companies in Q1 2020
Market Cap for Bio/Pharma Companies With and Without a COVID-19 Drug over Q1 2020
Q1 2020 Change in Market Cap by Company Market Cap Size
2. Market Cap for Top 20 Bio/Pharma Companies: Q1 2020 vs. 2019
Market Cap Change for Top 20 Bio/Pharma: Q1 2020 vs. 2019
Market Cap Change Q1 2020: Bayer AG
Market Cap Change Q1 2020: Gilead Sciences
Market Cap Change Q1 2020: Regeneron Pharmaceuticals
Q1 2020 Market Cap Change for Top 20 Bio/Pharma: With and Without a COVID-19 Drug
Market Cap Growth: Q1 2020 vs. 2019 Biggest Movers
Market Cap Change Q1 2020: AbbVie Inc
3. Drug Sales for Top 20 Bio/Pharma Companies vs. Market Cap
Global Total Drug Sales for Q1 2020 vs. Market Cap
4. Drug Sales for Top 20 Bio/Pharma Companies Q1 2020 vs. Q4 2019
Global Total Drug Sales Q1 2020 vs. Q4 2019
5. Drug Sales for Top 20 Bio/Pharma Companies vs. Archived Forecasts
Q1 2020 Actual Sales vs. Archived Global Analyst Consensus Sales Forecast for Top-Selling Drugs
Total Q1 2020 Actual Sales vs. Total Archived Global Analyst Consensus Sales Forecast
Key Findings
Appendix
Filed in: Pharmaceutical
Publisher : GlobalData